Table 3.

Top five results from dose optimisation for children 3–11 months old in the MORDOR and CHAT trials, with age cut-off determination and tolerance limits 15–30 mg/kg

Study (n)	Age cut-off (months)†	Dose 1, younger group	Dose 2, older group	Within limits		Underdose		Overdose
				N	%	N	%	N	%
MORDOR (3713)	3	120 mg (3 mL)	160 mg (4 mL)	3507	94.5	98	2.6	108	2.9
	4	120 mg (3 mL)	160 mg (4 mL)	3500	94.3	132	3.6	81	2.2
	3	160 mg (4 mL)	160 mg (4 mL)	3470	93.5	83	2.2	160	4.3
	4	160 mg (4 mL)	160 mg (4 mL)	3470	93.5	83	2.2	160	4.3
	5	120 mg (3 mL)	160 mg (4 mL)	3470	93.5	194	5.2	49	1.3
CHAT (5167)	5	120 mg (3 mL)	160 mg (4 mL)	4839	93.7	186	3.6	142	2.7
	4	120 mg (3 mL)	160 mg (4 mL)	4836	93.6	120	2.3	211	4.1
	6	120 mg (3 mL)	160 mg (4 mL)	4803	93.0	272	5.3	92	1.8
	3	120 mg (3 mL)	160 mg (4 mL)	4785	92.6	81	1.6	301	5.8
	7	120 mg (3 mL)	160 mg (4 mL)	4706	91.1	403	7.8	58	1.1

Result with highest accuracy is highlighted for each set of analyses.*

*Percentages may not sum to 100% due to rounding.

†Age cutoffs refer to the age at which the younger group ends. An age cut-off of 3 indicates a younger group of 3 months old and an older group of 4–11 months old, an age cut-off of 4 indicates a younger group of 3–4 months old and an older group of 5–11 months old, an age cut-off of 5 indicates a younger group of 3–5 months old and an older group of 6–11 months old.

CHAT, Child Health with Azithromycin Treatment; MORDOR, Macrolides Oraux pour le Réduire des Décès avec un Oeil sur la Résistance.